The single-use bioprocessing market size is expected to advance at a CAGR of 17.10% during 2022–2030, to reach USD 80.36 billion by 2030. This can be ascribed to the enhanced user protection via closed systems, reduced capital investment and commissioning time, and minimum risk of cross-contamination.
Biopharmaceutical development and production are the primary applications of single-use bioprocessing technology. The technology is utilized throughout the biopharmaceutical production workflow, from the preparation of buffer and media to the shipping and storage of intermediates and bulk biologics to vaccine bioreactor cultures. Several products used to implement techniques for bioprocessing are used only once. Manifold assemblies, single-use bioreactors, bioprocess containers and bags, single-use mixers, and outer support containers are some of the major products. Sterilization, cleaning, and maintenance of enormous bioreactors are just a few of the complicated bioproduction processes that can be eliminated by these products.
Based on deployment, the market is categorized into downstream bioprocessing, fermentation, and upstream bioprocessing. Among these, the downstream bioprocessing category held the largest revenue share in 2022. This is largely due to the surging use of membrane filtration in sterilization and the significance of concentration processes in the production of biopharmaceuticals and vaccines. Moreover, the downstream processing industry is being fueled by an increase in the demand for novel solutions, process optimization and cost reduction, and the use of centrifuges to separate biological particles from suspension.
The demand for biopharmaceuticals has experienced significant growth in the market, owing to the rising incidence of chronic illnesses worldwide and the increasing development of new drugs. Moreover, advanced biotechnological methods are frequently used to create biopharmaceuticals, which are medicines made from living cells or organisms. In the production of biopharmaceuticals, single-use systems are utilized. New drugs are also made possible by spending more money on research and development in life sciences.
For instance, the International Federation of Pharmaceutical Manufacturers and Association (IFPMA), a trade association of pharmaceutical companies based in Switzerland, stated that in 2020, 2748 new drugs for specific diseases, like cancer, were developed. There were 1535 new drugs developed for immunology and 1213 new drugs for infectious diseases.
Similarly, according to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the coming years. As a result, the demand for bioprocessing equipment, including downstream bio-processing controllers, is expected to expand in tandem with the rising need for biopharmaceuticals in the future.
To improve their positions in the market, companies are adopting merger and acquisition strategies. For instance, in June 2021, Avantor bought RIM Bio, a company in China that makes bioprocess bags and assemblies for one-time use for biopharmaceutical manufacturing. Avantor's single-use manufacturing network in the Americas and Europe would expand and its Changzhou (China) facility would serve as the company's first single-use manufacturing plant in the Asia-Pacific, Middle East, and Africa region.
The major single-use bioprocessing market players are Sartorius AG, Danaher Corporation, Thermo Fisher Scientific, Merck KGaA, and Boehringer Ingelheim International GmbH.